logo-loader
viewAIM ImmunoTech Inc.

Hemispherx Biopharma's stock soars on 'significant progress' in ovarian cancer study of Ampligen

The ovarian cancer study is being conducted at the University of Pittsburgh Medical Center

Newspaper headline
Hemispherx is now accruing patients for a second ovarian cancer clinical trial to evaluate Ampligen in combination with drug Pembrolizumab.

Shares of Hemispherx Biopharma (NYSEAMERICAN:HEB) soared Tuesday after the company announced “significant progress” in the study of its flagship drug Ampligen in treating ovarian cancer.

Hemispherx’s stock recently traded at $0.24 a share, up 41% on heavy volume.  

READ: Hemispherx Biopharma kicks off Phase 1 trial to treat advanced breast cancer with key drug Ampligen

The study currently is being conducted at the University of Pittsburgh Medical Center (UPMC), the company said in statement.

The Orlando, Florida-based company also noted it is now accruing patients for a second ovarian cancer clinical trial at UMPC to evaluate Ampligen in combination with drug Pembrolizumab.

Hemispherx also is studying separately whether Ampligen is effective in treating breast cancer in combination with Merck’s (NYSE:MRK) cancer drug Keytruda.

Contact the author: [email protected]

Follow him on Twitter @patrickmgraham

Quick facts: AIM ImmunoTech Inc.

Price: 2.755 USD

NYSE:AIM
Market: NYSE
Market Cap: $90.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc. named herein, including the promotion by the Company of AIM ImmunoTech Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

AIM Immunotech forms Phase 1/2a clinical trial agreement to fight the...

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive that it has struck a clinical trial agreement with Roswell Park Comprehensive Cancer Center to support its Phase 1/2a trial of Ampligen in combination with interferon alfa-2b, in cancer patients with the coronavirus. What's...

2 weeks, 1 day ago

2 min read